NCT03849768 2023-01-20
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Phase 3 Unknown
Clinical Trials
9 trialsNCT03758287 2022-06-22
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
Sunshine Lake Pharma Co., Ltd.
Phase 1/2 Unknown
NCT04390984 2021-01-11
Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Unknown
NCT04239833 2020-01-27
A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 3 Unknown
NCT03856697 2019-02-27
Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Phase 3 Unknown
NCT03381430 2017-12-22
Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR
Qilu Pharmaceutical Co., Ltd.
Phase NA Unknown
NCT03264794 2017-08-29
the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)
Jiangsu Famous Medical Technology Co., Ltd.
Phase 4 Unknown
NCT02906163 2016-09-19
First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy
SciClone Pharmaceuticals
Phase 1/2 Unknown
NCT01391260 2011-08-02
Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)
ZhuGuangYing
Phase 2 Unknown